The recent MJBizDaily column argues that cannabis genetics are the industry’s most valuable asset. This editorial outlines what that assertion means in practical terms for breeders, seedbanks, cultivators, product developers and regulators, identifies where evidence and uncertainty sit, and sets out pragmatic priorities for stewardship, record keeping and risk management.

Researchers at Yale School of Medicine report that the genetic architecture associated with trying or using cannabis diverges from the genetics linked to problematic use and addiction. For industry professionals, breeders and medical suppliers the distinction matters for research priorities, product development and public-health engagement.

MJBizDaily’s recent piece argues that the cannabis industry must give genetics a strategic role beyond marketing. For breeders, seedbanks and commercial growers that means clear provenance, investment in breeding and data, and active stewardship to protect diversity, IP and supply resilience. This editorial explains what the argument means in practical terms for professionals and where the industry will need attention next.